
When investing with retirement in mind, the goal is to own businesses that can remain relevant, profitable, and resilient over many years.
The types of companies that suit this approach tend to share a few traits. They operate in markets with long-term demand, they reinvest to stay ahead of competitors, and they have business models that can adapt as technology and customer needs evolve.
With that in mind, here are three ASX 200 stocks I would be comfortable holding through market cycles and all the way through to retirement.
Cochlear Ltd (ASX: COH)
Cochlear is one of the most respected healthcare shares listed on the Australian stock exchange.
It is the world leader in implantable hearing solutions, operating in a market supported by powerful demographic tailwinds. As populations age and access to healthcare improves globally, demand for hearing implants is expected to grow steadily over time.
What makes Cochlear particularly attractive for long-term investors is its competitive position. The company benefits from deep intellectual property, strong clinician relationships, and very high switching costs. Once a patient enters the Cochlear ecosystem, they often remain within it for life, supporting recurring revenue through upgrades and accessories.
This combination of essential healthcare, innovation, and long-term customer relationships makes Cochlear a classic buy and hold candidate.
Megaport Ltd (ASX: MP1)
Another ASX 200 stock I would be happy to hold until retirement is Megaport.
It is a very different type of retirement-style investment, but its long-term potential is compelling.
The company operates a global network-as-a-service platform, which allows businesses to connect quickly and securely to cloud providers and data centres. As more workloads move to the cloud and hybrid IT environments become the norm, demand for flexible, on-demand connectivity continues to grow.
Megaport’s business model is highly scalable. Once its network infrastructure is in place, incremental customers can be added at relatively low cost, creating the potential for strong operating leverage as revenue grows. It also recently completed the acquisition of Latitude, which has increased its total addressable market materially. This bodes well for its long-term growth outlook.
ResMed Inc. (ASX: RMD)
Lastly, I think ResMed would be a great long term pick. It combines defensive healthcare characteristics with genuine growth optionality.
ResMed is a global leader in sleep apnoea and respiratory care devices, operating in a market that remains significantly underdiagnosed. In fact, the sleep apnoea treatment market is estimated to be over 1 billion sufferers.
Beyond hardware, ResMed has been expanding its software and digital health offerings, building deeper relationships with patients and healthcare providers. This shift toward connected devices and data-driven care adds a layer of recurring revenue and enhances the durability of the business.
In light of this, I think this ASX 200 stock could be a great buy and hold option for Aussie investors.
The post The ASX 200 stocks I’d be happy to hold until retirement appeared first on The Motley Fool Australia.
Should you invest $1,000 in Cochlear Limited right now?
Before you buy Cochlear Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 18 November 2025
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- How I’d build a $1,000-a-month passive income from ASX shares
- Top brokers name 3 ASX shares to buy today
- 5 incredible ASX growth stocks to buy for 2026
- This might be the most underrated artificial intelligence ASX stock to own in 2026
- How to turn small ASX share investments into life-changing money
Motley Fool contributor James Mickleboro has positions in Cochlear, Megaport, and ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear, Megaport, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.








